SSRI Tapering for Coaches and Clinicians: Why There Is No One-Size-Fits-All Protocol

Roughly one in six American adults takes an antidepressant, and most have been on it for years. When psilocybin and other classic psychedelics reach FDA approval, a large share of the people who want them will be starting from inside that group. They cannot add a psychedelic on top of an SSRI, and coming off is the part almost no one has planned for.

Clinics that already run ketamine and Spravato programs are working through this problem now, with real patients. What follows is what that experience suggests about tapering, about telling withdrawal from relapse, and about the support a medicated client actually needs. Most of it applies whether you hold a prescription pad or not.

Most Clients Don’t Walk In Asking to Taper

Practitioners in this space report that very few clients arrive with “I want off my medication” as the opening request. Some clinic owners put the number around one in ten. The topic tends to surface later, during a medical history, or after a few sessions when the client has started to feel better and begins to wonder what else is possible.

That puts a quiet responsibility on the practitioner. If the subject only comes up when the client raises it, most medicated clients will go years without anyone revisiting the decision. The prescriber renews the refill. The psychedelic practitioner says come back when you’re off it. Nobody owns the middle.

Paul F. Austin frames it with a question: how long would you wear a cast before you thought it was time to start walking on that leg again? The cast was not wrong. It was never meant to be permanent, and the day you put it on is the day you should start talking about the day it comes off. An SSRI can be the right tool for stabilizing someone through a severe episode. A practitioner who never asks about the exit is not serving the client’s long-term sovereignty.

Start With the Reason, Not the Schedule

Before any taper begins, the better question is why. What is the client trying to get back?

The answers are usually specific. Sexual function. The ability to cry at a funeral. A fuller range of emotion. Those motivations define what success looks like. A taper that technically succeeds but leaves the client feeling no different has not done what they came for.

Standardized measures like the PHQ-9 belong in the chart. The question that guides the work is simpler: is your life better? If yes, the client has the footing to take on a harder phase. If not yet, the taper can wait.

Why Tapering Resists a Single Protocol

Every antidepressant clears the body at a different rate. Fluoxetine (Prozac) has such a long half-life that a person can miss two doses and feel nothing. Venlafaxine (Effexor) clears so quickly that missing one dose can bring on the electrical jolts people call brain zaps by the next day. A 2024 meta-analysis of 79 studies in The Lancet Psychiatry found the same pattern at scale: venlafaxine was among the medications with the highest rates of discontinuation symptoms, fluoxetine among the lowest.

Then layer in how long the person has been on the drug, the dose, whether they take more than one psychiatric medication, their anxiety baseline, their support at home, and what they are tapering toward. Any one of those changes the plan.

This is why practitioners who do this work consistently refuse to hand over a protocol. As Remi Drozd, DO, founder of Lucid Therapeutics in Santa Barbara, puts it, “We taper a person.” Drozd also holds a standard he calls earning the taper: clients first show, through their engagement and the changes they make in their lives, that they can handle what comes next. Then the taper conversation starts.

A related discipline is changing one variable at a time. A client who starts ketamine, stops their SSRI, and begins a new medication in the same month has made it impossible to tell which change is producing which effect. Sequence matters more than speed.

Withdrawal or Relapse? The Call That Decides Everything

A client tapers off an SSRI. The first week or two go fine. A few weeks in, the low mood returns, or the anxiety, or the insomnia. The client concludes they were depressed all along and goes back on. Sometimes that conclusion is correct. Often it is not.

The Lancet Psychiatry meta-analysis found that about one in three people report symptoms after stopping an antidepressant. Accounting for people who reported the same symptoms after stopping a placebo, roughly one in six had symptoms caused directly by the drug, and about one in 35 had severe ones. Other analyses put the incidence higher. The literature disagrees on the size of the problem, not on the fact that risk rises the longer someone has been medicated.

What makes this hard is that discontinuation symptoms look like the original condition returning. Low mood, anxiety, irritability, and poor sleep show up in both. The distinction lives in timing, symptom profile, and how things move over days and weeks. It can be taught, and very few practitioners have been taught it.

One piece the Psychedelic Coaching Institute considers central: the drug clearing the body is not the same event as the body adjusting to its absence. Clearance takes days. The adaptation built up over years of daily dosing takes far longer to unwind, and that unwinding is what clients feel. “Wait a few weeks for it to leave your system” is a widespread belief, and it is not a safe one.

Where Ketamine Fits

Ketamine works through glutamate rather than serotonin, so it does not compete with an SSRI the way a classic psychedelic would. A client can begin ketamine while still fully medicated, feel benefits within hours or days rather than the weeks an SSRI takes, and approach the taper from a more stable position.

Clinics running this model describe the sequence as: meet the client where they are, begin ketamine, let them earn the taper, then support the taper with ketamine still in place. It tends to soften the discontinuation period without erasing it.

One access note: Spravato, the insurance-covered nasal esketamine, is indicated for treatment-resistant depression, so a client generally needs two documented failed antidepressant trials to qualify. For someone already on multiple medications, that bar is usually met.

The Scaffold That Keeps People Off

Coming off is the shorter task. Staying off is the longer one, and it is where most support models are thinnest.

Clinicians preparing for psychedelic approval are already sketching what a full structure needs: a workbook and journal, a therapist or integration coach trained in non-ordinary states, a group of people tapering at the same time who meet weekly, and nervous system tools the client can reach for when the widened emotional range starts to feel like too much. All of it running for six months at minimum.

That last point is one the Institute puts at the center of its own training. Breath, somatic practice, sleep, movement, and targeted supplementation are what make the expanded emotional window tolerable once the medication’s brakes come off. A taper without that stack behind it is a taper likely to reverse.

What Approval Will Change

The regulatory picture moved fast in 2026. In July the FDA published its first final guidance on psychedelic clinical investigations, and it reads in places like a clinic blueprint: two monitors present for the entire dosing session, and a physician reachable on site within 15 minutes. A public hearing on therapeutic use is set for September 14. Compass Pathways expects to complete its psilocybin application by year end, and Eli Lilly paid $2.8 billion in July for a developer whose lead product is an intranasal 5-MeO-DMT.

For an existing clinic, a six-hour psilocybin session is a different operational animal from a two-hour ketamine one. Rooms, staffing, and reimbursement all get rethought. But the question underneath all of it is the washout. No payer wants to spend a six-hour room on a patient whose SSRI is still blunting the medicine. So the taper becomes the gate, and whoever can guide a medicated client through it safely, and keep them stable on the other side, becomes the practitioner the referrals go to.

Summary: The Taper Is the Work

Psychedelic approval is going to expose a gap that has been there for years. Millions of people on long-term antidepressants will want access, and most will need to come off first. There is no single protocol for that, because there is no single client. What exists instead is a set of judgments: why this person wants off, what they are tapering from and toward, how to read withdrawal against relapse, and what support has to be in place before the first dose is reduced.

That gap is exactly what the SSRI Deprescribing & Psychedelic Readiness certification at the Psychedelic Coaching Institute was built to close. David Rabin, M.D., Ph.D. teaches the full sequence across six live sessions, from readiness assessment through the taper, the ketamine bridge, and the nervous system support that keeps clients off, with a written scope-of-practice position you build during the program. If you already have medicated clients and want to stop referring them away, start there. [Link]